Opus Genetics
IRDOpus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases.
Earnings
Next report
Nov 11, 2026 (In 1 week)Financials
Q2 2026Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases. The company utilizes adeno-associated virus (AAV) vectors to deliver functional genes directly to the retina, targeting rare genetic mutations with high unmet medical needs. Its value proposition is built on a portfolio approach that combines durable, one-time gene therapies with a small-molecule platform for common ophthalmic disorders.
A clinical-stage innovator in the rare ophthalmic gene therapy space with a diversified pipeline and a strategic commercial partnership for its lead small-molecule product.
FAQ
- What is Opus Genetics's market cap?
- Opus Genetics (IRD) has a market capitalization of $303.7M and trades on XNAS.
- What is Opus Genetics's revenue and profitability?
- Opus Genetics generated $9.9M in trailing twelve-month revenue with a net loss of $107.6M, representing a net margin of -1091.8%. The latest reported period is Q2 2026.
- Who are Opus Genetics's competitors?
- Opus Genetics's key competitors include MeiraGTX, Lenz Therapeutics, Lineage Cell Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Opus Genetics partner with?
- Opus Genetics's notable partners include Viatris, Inc., University of Pennsylvania, University of Florida, and others.
- Where is Opus Genetics headquartered?
- Opus Genetics is headquartered in United States of America and employs approximately 14 people. It has been publicly traded since 2020.
